Commentary: Scheme has benefited patients.
Compston
Alastair
A
Department of Clinical Neurosciences, University of Cambridge, Cambridge. alastair.compston@medschl.cam.ac.uk
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D000068717:Glatiramer Acetate; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D007372:Interferons / Q000191:economics / Q000600:supply & distribution; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D010455:Peptides / Q000191:economics / Q000600:supply & distribution; D019057:Quality-Adjusted Life Years; D020414:Risk Sharing, Financial; D013222:State Medicine / Q000191:economics
D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons